KLRS

MKT CAP:$114M

Kalaris Therapeutics Inc

Market Cap

$114M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$6.16-$2.14 (-25.78%)

Apr 24, 2026

Company Details

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with...

CEO

Andrew Oxtoby

IPO Date

Jul 30, 2020

Website

kalaristx.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$43M

EPS (Diluted)

-$4.21

Free Cash Flow

-$43M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 13, 2026

PENDING

FY 2025

Dec 30, 2025

$0EPS -$2.85

Q4 2025

Dec 30, 2025

$0EPS -$0.44

Q3 2025

Sep 30, 2025

$0EPS -$0.64

Q2 2025

Jun 30, 2025

$0EPS -$0.61

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$846.0K	-$43M
Q2 22	$0	-$426.0K	-$45M
Q3 22	$0	-$199.0K	-$43M
Q4 22	$0	-$1M	-$40M
Q1 23	$0	-$547.0K	-$43M
Q2 23	$0	$0	-$47M
Q3 23	$0	-$4M	-$47M
Q4 23	$0	$0	-$3M
Q1 24	$0	$0	-$3M
Q2 24	$0	$0	-$4M
Q3 24	$0	$0	-$38M
Q4 24	$0	$0	-$20M
Q1 25	$0	$0	-$10M
Q2 25	$0	$0	-$12M
Q3 25	$0	$0	-$13M
Q4 25	$0	-$10.0K	-$11M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$28M	-$28M
Q1 22	-$46M	-$46M
Q2 22	-$29M	-$29M
Q3 22	-$35M	-$35M
Q4 22	-$32M	-$32M
Q1 23	-$32M	-$32M
Q2 23	-$27M	-$27M
Q3 23	-$34M	-$34M
Q4 23	-$4M	-$4M
Q1 24	-$5M	-$5M
Q2 24	-$4M	-$4M
Q3 24	-$4M	-$4M
Q1 25	-$7M	-$7M
Q2 25	-$15M	-$15M
Q3 25	-$11M	-$12M
Q4 25	-$9M	-$9M

Capital Expenditures

Quarter	CapEx
Q4 21	$370.0K
Q1 22	$0
Q2 22	$0
Q3 22	$0
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$183.0K
Q4 25	$17.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+40.0%
Q2 22	—	+18.5%
Q3 22	—	-5.6%
Q4 22	—	-27.5%
Q1 23	—	+0.1%
Q2 23	—	+6.0%
Q3 23	—	+9.3%
Q4 23	—	-91.4%
Q1 24	—	-94.1%
Q2 24	—	-91.1%
Q3 24	—	-19.4%
Q4 24	—	+463.6%
Q1 25	—	+304.0%
Q2 25	—	+192.7%
Q3 25	—	-66.3%
Q4 25	—	-44.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$0	—
Q1 22	$0	—
Q2 22	$0	—
Q3 22	$0	—
Q4 22	$0	—
Q1 23	$0	—
Q2 23	$0	—
Q3 23	$0	—
Q4 23	$31.0K	—
Q1 24	$31.0K	—
Q2 24	$322.0K	—
Q3 24	$262.0K	—
Q1 25	$374.0K	—
Q2 25	$0	—
Q3 25	$638.0K	—
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$28M	—	$14M
Q2 22	$31M	—	$13M
Q3 22	$30M	—	$13M
Q4 22	$27M	—	$12M
Q1 23	$30M	—	$13M
Q2 23	$35M	—	$12M
Q3 23	$31M	—	$13M
Q4 23	$3M	$498.0K	—
Q1 24	$2M	$602.0K	—
Q2 24	$3M	$976.0K	—
Q3 24	$36M	$2M	—
Q4 24	$320.0K	—	$19M
Q1 25	$6M	$4M	—
Q2 25	$8M	$4M	—
Q3 25	$9M	$4M	—
Q4 25	$7M	—	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$100M	$101M	$201M
Q2 22	$71M	$102M	$173M
Q3 22	$124M	$140M	$264M
Q4 22	$106M	$128M	$234M
Q1 23	$116M	$87M	$203M
Q2 23	$197M	$50M	$247M
Q3 23	$96M	$118M	$213M
Q4 23	$3M	$0	$3M
Q1 24	$86M	$54M	$141M
Q2 24	$105M	$25M	$130M
Q3 24	$2M	$0	$2M
Q4 24	$118M	$0	$118M
Q1 25	$101M	$0	$101M
Q2 25	$88M	$0	$88M
Q3 25	$42M	$35M	$77M
Q4 25	$98M	$20M	$118M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	3M	+0.7%	+2.9%
Q2 22	3M	+0.7%	+3.4%
Q3 22	4M	+31.8%	+34.9%
Q4 22	4M	+9.6%	+46.5%
Q1 23	4M	+0.2%	+45.8%
Q2 23	4M	+1.4%	+46.8%
Q3 23	5M	+20.4%	+34.1%
Q4 23	5M	+0.1%	+22.4%
Q1 24	5M	+0.5%	+22.8%
Q2 24	5M	0.0%	+21.1%
Q3 24	5M	0.0%	+0.6%
Q4 24	5M	+0.8%	+1.3%
Q1 25	4M	-19.3%	-18.6%
Q2 25	19M	+361.4%	+275.4%
Q3 25	19M	+0.0%	+275.4%
Q4 25	23M	+22.5%	+356.2%

Shares Outstanding